
-
Nektar Therapeutics NasdaqCM:NKTR Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Location: 455 Mission Bay Boulevard South, San Francisco, CA, 94158, United States | Website: https://www.nektar.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
105.6M
Cash
218.6M
Avg Qtr Burn
-44.22M
Short % of Float
5.81%
Insider Ownership
1.31%
Institutional Own.
67.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezpegaldesleukin (NKTR-358) Details Autoimmune disease, Alopecia areata | Phase 2b Data readout | |
Rezpegaldesleukin (NKTR-358) Details Autoimmune disease, Atopic dermatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
NKTR-255 + Avelumab Details Urothelial carcinoma, Cancer | Phase 2 Data readout | |
NKTR-255 Details Cancer, B-cell lymphoma | Phase 2 Update | |
NKTR-255 (IL-15R agonist) + Cetuximab (Erbitux) (EGFR inhibitor) Details Colorectal cancer , Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update | |
NKTR-255 (IL-15 agonist) +/- Daratumumab Details Non-Hodgkin lymphoma, Multiple myeloma, Cancer | Phase 1/2 Update | |
NKTR-255 (IL-15 agonist) + C-TIL051 Details Cancer, Non-small cell lung carcinoma | Phase 1 Data readout | |
NKTR-0165 Details Inflammatory disease | IND Submission | |
NKTR-358 Details Autoimmune disease, Ulcerative colitis | Failed Discontinued | |
Bempegaldesleukin (NKTR 214) + Opdivo (Nivolumab) Details Cancer, Melanoma | Failed Discontinued | |
Dapirolizumab Pegol (anti-CD40L) Details Systemic lupus erythematosus, Autoimmune disease | Failed Discontinued | |
Bempegaldesleukin+ KEYTRUDA® (pembrolizumab) (PROPEL) Details Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ Opdivo (Nivolumab) Details Bladder cancer, Cancer | Failed Discontinued | |
Bempegaldesleukin (BEMPEG) + KEYTRUDA (pembrolizumab) Details Head and neck cancer, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details Urothelial cancer, Cancer, Bladder cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214) + OPDIVO (Nivolumab) Details Solid tumor/s, Cancer | Failed Discontinued | |
Onzeald (etirinotecan pegol) Details Metastatic breast cancer to brain, Cancer | Failed Discontinued | |
Bempegaldesleukin (NKTR-214) + Opdivo (Nivolumab) Details Renal cell carcinoma, Cancer | Failed Discontinued | |
Bempegaldesleukin (NK-214) + VB10.NEO Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued | |
Rezpegaldesleukin (LY3471851) (NKTR-358) Details Autoimmune disease, Systemic lupus erythematosus | Failed Discontinued | |
NKTR-262 (with bempegaldesleukin) Details Solid tumor/s, Cancer | Failed Discontinued |